Leadership

Bindi Chudgar is one of the most distinguished women in the corporate world. Since inception, Mrs. Chudgar’s entrepreneurial intellect has ensured that Lambda grows both organically and inorganically to become a truly global CRO. Over the years, her progressive vision and values have helped Lambda create a niche to stand apart from the rest in the CRO industry. Meticulous by nature, she overlooks Lambda’s Corporate M&A, Strategy, Finance and Human Resources embracing the best of contemporary and conventional ideologies which are the best fit for the organization globally.

Bindi’s keenness on high-quality standards is best reflected in Lambda’s exceptional regulatory track record. The organization’s various facilities across the world have undergone successful accreditations by some of the world’s topmost regulatory agencies. It is her visionary genius and strong-willed determination that helps Lambda transcend geographical boundaries to excel in the world’s most promising pharmaceutical markets, besides continually augmenting and diversifying its service portfolio and expertise.

She has always been a people’s person. She believes in building an engaging and empowering work culture which are the foundation and key drivers for building a strong and successful organization.
She is determined to continue raising the bar for the development and commercialization of new medical therapies worldwide, through Lambda.

Mr. Luke S Gill, the Chief Executive Officer of Lambda & Novum, is a seasoned leader with a remarkable track record in clinical drug development spanning over 25 years. His goal of fortifying strategic insights, fostering innovative solutions, and refining operational expertise drives the convergence of Lambda and Novum through aligned strategies and processes.

Luke holds a Neuro & Molecular Pharmacology Master’s degree and has authored numerous publications focusing on cell signaling pathways at the University of Bristol. Prior to joining our team, Luke held pivotal roles in prominent CROs such as TFS, IQVIA, PPD, and Premier Research, demonstrating leadership prowess through successful collaborations with both small and large biopharma companies. His expertise spans diverse therapeutic domains, including cell therapies, targeted small molecules, and immune-oncology, across rare indications, solid tumors, and hematological malignancies.

A strategic thinker, he excels in designing and delivering pivotal clinical studies while exhibiting a consultative approach in developing innovative solutions. Luke Gill epitomizes our commitment to excellence and innovation, driving our mission of advancing global clinical research forward.

Gail has 24 years of experience within the science and clinical medicine fields; 20 years of that experience is with Novum. She has held a wide range of positions with increasing responsibility. In a career spanning cost analysis, project management and study conduct, she currently has a senior leadership role with Novum. Her understanding of the complexity of clinical research has helped her to direct the management and daily operations of all clinical endpoint studies and data management services. She has helped to establish the one-of-a-kind Novum Clinical Research Associate Academy. In this innovative program, clinical research associates receive structured, comprehensive training in all aspects of clinical research.

Gail is a member of the Society of Clinical Research Professionals and the Society of Clinical Research Associates.

Niraj has more than 18 years of research experience working at CROs and Pharmaceutical companies, supporting the early and late phase clinical trials. Before joining Novum, Mr. Shethji served at Sun Pharmaceuticals, Pharma Medica Research, Biovail Corp. and Watson Pharmaceuticals (currently Teva) in variety of roles and increasing responsibilities. He joined Novum in 2011 to provide scientific leadership to the talented team of scientists, technical writers, statisticians and programmers. In addition to his broad experience with the conventional oral dosage forms (solid/liquid), he gained wide-spread exposure to the design and conduct of the biostudies for complex dosage forms such as transdermal, topical (including corticosteroids), injectable, nasal/inhalation, vaginal/rectal products.

He has hands on experience in developing study designs and protocols for the NDA/ANDA/505b2 submissions, statistical evaluation/presentation of data and generating high-quality study reports. His diverse experience in fields of PK, PD, bioanalysis, biostatistics, efficacy trials and regulatory sciences assists in directing Novum team in day-to-day functions and guiding clients in their development/submission strategies. He has been greatly involved with Novum’s project management in providing the scientific and operational support to meet client’s expectations. He received his Masters of Pharmacy (Pharmacology) and BS in Pharmacy from University of Pune.

Netal has over 18 years of progressive experience in Clinical Research and Pharmaceutical domain. His research experience includes design, operations, management, strategic thinking, and business development of early and late phase studies globally.

Netal has hands-on experience conducting early and late phase clinical research Studies in various therapeutic areas including oncology, psychiatry, gastro-enterology, diabetes, skin diseases. He has extensive regulatory interaction experience with the major regulatory authorities such as USFDA, Health Canada, MHRA, ANSM, and SCC.

Netal holds MD (Pharmacology) and MBBS degrees form M S University, India. He has recently earned Global Executive MBA-Health care and life sciences from Rotman Business school, University of Toronto. He is certified clinical research professional from SOCRA (Society of Clinical Research Associates). Netal is Scientific Advisory Board Member for clinical research at York University.

David has 20 years of experience in clinical research. During this time, he has served in leadership roles throughout clinical, project management, and study management. His experience spans across many different drug delivery formulations (topical, oral, injectable, inhalation, etc.).

He has successfully managed diverse teams across different departments, both internally and externally. He is well-versed in study planning and logistics, allowing him to better serve our diverse client base.

David received his BS in Biomedical Science from Texas A&M University. Additionally, he received his Master of Business Administration and Master of Healthcare Administration from the University of Houston – Clear Lake.

Vrajesh possesses 19 years of progressive experience in the field of Finance during which he held various leadership roles serving Automobile, Foreign Trade and Pharmaceutical Research Industries.

Throughout his career, he has demonstrated a strong ability to deliver results on key business objectives with a focus on continuous improvement. Vrajesh has implemented innovative solutions that have streamlined processes and improved efficiencies for the organization. With his deep understanding of finance and accounting principles, Vrajesh brings extensive experience in FP&A (Financial planning & analysis) driving growth and creating value for the organization.

Vrajesh is qualified as a Chartered Accountant from India. He further graduated as a Chartered Professional Accountant from Canada. Vrajesh currently heads the finance team for Novum across North America.

Cathy has been in the Clinical Research Industry for over 21 years, including 11 years associated with the Lambda Group. She brings extensive experience in both healthy volunteer and patient studies across Phases I–IV, including NCE and Generic trials. Her expertise spans various aspects of clinical trials, including feasibility, QC/QA, and Business Development. A strategic thinker, Cathy supports early and late-phase studies globally, with international expertise in markets across Asia, Europe, and South America.

Her goal is to maximize Lambda & Novum’s business development and clinical trials potential by supporting every aspect of the studies. She aligns her goals with the strategic vision of Lambda & Novum and works with top-tier clients in the U.S. and globally to drive growth. Cathy also provides invaluable support in the Clinical Trials domain.

Cathy holds a Clinical Trials Management Certificate from the University of Delaware, a specialization in Marketing Research, a Postgraduate Degree in Marketing, and a BA in International Trade from Colombia.

Ferran is a seasoned professional with 11 years of experience in the pharmaceutical sector. His goal of generating new business through relationships, connecting companies, and identifying synergies drives Lambda’s success through aligned strategies and processes.

Ferran holds a degree in International Trade and has demonstrated leadership prowess through successful collaborations with various companies. His expertise spans diverse domains, including business development and strategic partnerships.

With extensive global experience, Ferran has successfully collaborated with companies across all continents. His ability to understand and negotiate with diverse cultures ensures consistently mutually beneficial outcomes. Ferran’s approach, characterized by strategic thinking and innovative solutions, makes him a key driver in advancing the pharmaceutical industry.